1Belenguer-Guallar I,Jim6nez-Soriano Y, Claramunt-Lozano A. Treat ment of recurrent aphthous stomatitis.A literature review [J]. J Clin Exp Dent,2014,6(2):168-174.
2Revuz J, Guillaume JC, Janier M, et al. Crossover study of thalido- mide vs placebo in severe recurrent aphthous stomatitis [J]. Arch Dermatol, 1990,126 (7) :923 -927.
3Jacobson JM,Greenspan J S, Spritzler J,et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunode- fieiency virus infection[J]. N Engl J Med,1997,336 (21):1487-1493.
4Ramirez-Amador VA,Esquivel-Pedraza L,Ponee-de-Leon S,et al. T- halidomide as therapy for human immunodeficieney virus related oral uleers:a double blind placebo controlled clinical trial [J]. Clin Infect Dis, 1999,28 (4) :892-894.
5Hello M,Barbarot S,Bastuji-Garin S,et al. Use of thalidomide for sev- er recurrent aphthous stomatitis: a muhicenter cohort analysis 0]. Medicine,2010,89(3): 176-182.
6Bastuji-Garin S,Ochonisky S,Bouche P,et al. Incidence and risk fac- tors for thalidomide neuropathy: a prospective study of 135 dermato- logic patients [J]. J Invest Dermtol,2002,119(5):987-1020.
7Tosi P,Zamagni E,Cellini C,et al. Neurological toxicity of long-term (>lyr) thalidomide therapy in patients with muhipie myaloma [J]. Eur J Haematol,2005,74 (3) :212-216.
8Mileshkin L,Stark R,Day B,et al. Development of Neuropathy in Pa- tients With Myeloma Treated With Thalidomide: Patterns of Occur- rence and the Role of Electrophysiologic Monitoring [J]. J Clin On- col,2006,24(27):4507 -4514.
9Hamuryudan V,Mat C,Saip S,et al. Thalidomide in the treatment of the mucocutaneous lesions of Behcet syndrome. A randomized, dou- ble-blind, placebo controlled trial Eli. Ann Intern Med,1998,128 (6): 443 -459.
10Wazieres B,Gil H,Magy N,et al with low doses of thalidomide 07 Interne,1999,20 (7) :567-570.
2Jacobson JM, Greenspan JS, Spritzler J, et al. Thalido- mide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases IDS Clinical Trials Group[J]. N Engl J Med, 1997, 336 (21): 1487- 1493.
3Ramirez-Amador VA, Esquivel-Pedraza L, Po0ce-;-de- Leon S, et al. Thalidomide as therapy for human": mmuno- deficiency virus-related oral ulcers: A double-blind place- bo-controlled clinical trial[J]. Clin Infect Dis, 1999, 28 (4) .. 892-894.
4Hamuryudan V, Mat C, Saip S, et al. Thalidonaide in the treatment of the mucocutaneous lesions of the Behqet syndrome A randomized, double-blind, placebo-controlled trial[J]. Ann Intern Med, 1998, 128(6):443-450.
5Hello M, Barbarot S, Bastuji-Garin S, et al. Use of tha- lidomide for severe recurrent aphthous stomatitis: A multicenter cohort analysis[J]. Medicine (Baltimore), 2010, 89(3) : 176-182.
6李秉琦.口腔黏膜病学[M].3版.北京:人民卫生出版社,2008:58-59.
7Juni P,Altman DG,Eger M.Assessing the quality of controlled clinical trails[J].BMJ,2001,323(7303):42-46.
8Revuz J,Claude J Guillaume,et al.Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis[J].Arch Dermatol,1990,126:923-927.
